| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2022-06-10 |
| タイトル |
|
|
タイトル |
Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
Pembrolizumab |
| キーワード |
|
|
主題 |
nephrotic syndrome |
| キーワード |
|
|
主題 |
acute kidney injury |
| キーワード |
|
|
主題 |
lung cancer |
| キーワード |
|
|
主題 |
withdrawal from hemodialysis |
| キーワード |
|
|
主題 |
immune checkpoint inhibitor |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Ishibuchi, Kento
Iwakura, Takamasa
Kaneko, Mai
Fukasawa, Hirotaka
Furuya, Ryuichi
|
| 書誌情報 |
CEN Case Reports
巻 9,
号 3,
p. 215-219,
発行日 2020-08
|
| 出版者 |
|
|
出版者 |
Springer Nature |
| 出版者 |
|
|
出版者 |
日本腎臓学会 = Japanese Society of Nephrology |
| 権利 |
|
|
権利情報 |
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s13730-020-00462-0 |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
A 70-year-old man diagnosed with lung adenocarcinoma was referred to our department for an evaluation of acute onset of nephrotic syndrome with acute kidney injury (AKI) after the 7th course of pembrolizumab treatment. Renal biopsy could not be performed because he needed anticoagulation therapy for venous thrombosis. Pembrolizumab was discontinued, and prednisolone was started. Hemodialysis was also started because oliguria was not resolved, and dyspnea due to pulmonary congestion appeared even with the high dose of diuretics. Hemodialysis was successfully withdrawn within 5 weeks duration because of renal function recovery and increase of urine volume. Complete remission was achieved 4 months after initiating prednisolone. He has never experienced hemodialysis again and remains remission of nephrotic syndrome even the dose of prednisolone was tapered for 8 months. Renal pathology in the current case was uncertain. However, minimal change disease seemed to be a plausible cause of nephrotic syndrome with AKI because of a good response to steroid therapy and acute onset of nephrotic syndrome. In addition, renal pathology in all of the reported cases of pembrolizumab-associated nephrotic syndrome with AKI was minimal change disease. Our case shows for the first time that renal function could be reversible with prednisolone in pembrolizumab-associated nephrotic syndrome with severe AKI even after progression of renal failure which needs dialysis. |
| EISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
2192-4449 |
| PubMed番号 |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
PMID |
|
|
関連識別子 |
32170578 |
| 医中誌論文ID |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
ICHUSHI |
|
|
関連識別子 |
2021108756 |
| 出版社DOI |
|
|
関連タイプ |
isVersionOf |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s13730-020-00462-0 |
| 著者版フラグ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
CEN Case Rep-9-215.pdf (694.1 kB)
